IBS AG

  • WKN: 622840
  • ISIN: DE0006228406
  • Land: Deutschland

Nachricht vom 19.06.2012 | 18:27

DGAP-DD: IBS AG excellence, collaboration, manufacturing english



Notification concerning transactions by persons performing managerial
responsibilities pursuant to section 15a of the WpHG

Directors' Dealings notification transmitted by DGAP - a company of
EquityStory AG.
The person with duty of notification is solely responsible for the content
of this announcement.
---------------------------------------------------------------------------

Details of the person subject to the disclosure requirement
Last name: Dr. Schröder
First name: Klaus-Jürgen
Company: IBS AG

Position: Member of a managing body

Information about the transaction with duty of notification

Description of the financial instrument: Shares
ISIN/WKN of the financial instrument: DE0006228406
Type of transaction: Sale
Date: 30.03.2012
Price: 5.60
Currency: EUR
No. of items: 2705630
Total amount traded: 15151528
Place: over the counter

Explanation for publication:

Fulfilment of the conditions of the over-the-counter-sale to Siemens
Industry Automation Holding AG, carried out in accordance with §§ 10, 23,
27 of the German Securities Acquisition and Takeover Act (WpÜG) and already
announced within the scope of the takeover bid

Information about the company with duty of publication

Issuer: IBS AG excellence, collaboration, manufacturing
Rathausstrasse 56
56203 Höhr-Grenzhausen
Deutschland
ISIN: DE0006228406
WKN: 622840


End of Directors' Dealings Notification 
(c) DGAP 19.06.2012

DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

ID 15479

Anleihe im Fokus

7,75% p.a. - Rendite aus Familienhand

– Zeichnungsstart: 23. Mai – Börse Frankfurt
– Zeichnung ab 1.000 Euro
– Laufzeit 5 Jahre
– WKN: A1TNA7
– 100% Rückzahlungskurs

GBC-Fokusbox

Syzygy AG: Aktie kaufen

Die nach den ersten drei Monaten des laufenden Jahres von Syzygy präsentierten Zahlen liegen im Rahmen unserer Erwartungen. Angesichts unserer unveränderten Prognosen behalten wir das bisherige Kursziel von 5 € bei und erneuern das Rating KAUFEN.

Aktueller Webcast

Allianz SE

Analysts' conference call on 1Q 2013

15. Mai 2013

Aktuelle Research-Studie

Orad Hi-Tec Systems Ltd

Original-Research: Orad Hi Tec Systems (von VEM Aktienbank AG): Kaufen

21. Mai 2013